Is InMed Pharmaceuticals Inc. (INM) Halal?
Shariah Screening — 5 Standards
Based on financial data from June 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 27.6% / 30% | 412.4% / 30% | 17.3% / 30% | 3.15% / 5% | ✗ NOT HALAL |
| DJIM | 27.6% / 33% | 412.4% / 33% | 17.3% / 33% | 3.15% / 5% | ✗ NOT HALAL |
| MSCI | 4.8% / 33% | 71.1% / 33% | 3.0% / 33% | 3.15% / 5% | ✗ NOT HALAL |
| S&P | 27.6% / 33% | 412.4% / 33% | 17.3% / 33% | 3.15% / 5% | ✗ NOT HALAL |
| FTSE | 4.8% / 33% | 71.1% / 33% | 3.0% / 50% | 3.15% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 29.7% | |
| Operating Margin | -258.6% | |
| Net Margin | -170.1% | |
| Return on Equity (ROE) | -97.2% | |
| Return on Assets (ROA) | -49.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$8M |
| Free Cash Flow | -$8M |
| Total Debt | $741,262 |
| Debt-to-Equity | 5.5 |
| Current Ratio | 5.9 |
| Total Assets | $16M |
Price & Trading
| Last Close | $0.68 |
| 50-Day MA | $0.91 |
| 200-Day MA | $1.77 |
| Avg Volume | 104K |
| Beta | 0.5 |
|
52-Week Range
$0.59
| |
About InMed Pharmaceuticals Inc. (INM)
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is InMed Pharmaceuticals Inc. (INM) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), InMed Pharmaceuticals Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is InMed Pharmaceuticals Inc.'s debt ratio?
InMed Pharmaceuticals Inc.'s debt ratio is 27.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 4.8%.
What are InMed Pharmaceuticals Inc.'s key financial metrics?
InMed Pharmaceuticals Inc. has a market capitalization of $2M, and revenue of $5M. The company maintains a gross margin of 29.7% and a net margin of -170.1%. Return on equity stands at -97.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.